BioBrooks Andrews joined EW in 2013 as an Associate, was promoted to Vice President in 2014 and to Principal in 2017. Mr. Andrews has played a key role on the Board of Directors of EW growth equity portfolio companies AxoGen, BreatheAmerica, Corium, Cota, EyePoint Pharmaceuticals, Metabolon, and Xenex and formerly, ProteinSimple. Prior to joining EW, Mr. Andrews worked at Friedman Fleischer & Lowe (“FFL”), a growth- ....
Education